The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells <i>In vitro</i> and <i>In vivo</i>

2009204 citationsJournal Articlebronze Open Access

Authors

Hiroshi Ikeda · Dana-Farber Cancer Institute

Teru Hideshima · Dana-Farber Cancer Institute

Mariateresa Fulciniti · Dana-Farber Cancer Institute

Robert J. Lutz · ImmunoGen (United States)

Hiroshi Yasui · Dana-Farber Cancer Institute

Yutaka Okawa · Dana-Farber Cancer Institute

Tanyel Kiziltepe

Abstract

These results provide the preclinical framework supporting evaluation of nBT062-maytansinoid derivatives in clinical trials to improve patient outcome in MM.

Topics & Keywords

Multiple Myeloma Research and Treatments Monoclonal and Polyclonal Antibodies Research HER2/EGFR in Cancer Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 15, Issue 12, pp. 4028-4037

DOI: 10.1158/1078-0432.ccr-08-2867

Field-Weighted Citation Impact: 9.78